Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

Boehringer Ingelheim & LEO Pharma partner to commercialize and further develop Spevigo: Ingelheim, Germany Wednesday, July 16, 2025, 15:00 Hrs [IST] Boehringer Ingelheim, a biopha ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.

Pioneer in RNA research who gave children with SMA a future Sabine Löwer Communications Boehringer Ingelheim St ...

The Delaware Supreme Court rejected the legitimacy of expert testimony linking the heartburn drug Zantac to cancer, in a ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Delaware's highest court ruled on Thursday that patients suing drugmakers GSK, Pfizer, Sanofi and Boehringer Ingelheim cannot ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...